Analyst Price Target is $10.60
▲ +208.14% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Fortress Biotech in the last 3 months. The average price target is $10.60, with a high forecast of $21.00 and a low forecast of $5.00. The average price target represents a 208.14% upside from the last price of $3.44.
Current Consensus is
The current consensus among 6 polled investment analysts is to buy stock in Fortress Biotech. This Buy consensus rating has held steady for over two years.
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the following Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded on June 28, 2006 and is headquartered in New York, NY.